(CercleFinance.com) – Quantum Genomics announces that the presentation of the results of its phase III FRESH study, in resistant hypertension, will finally take place on November 7, 2022.
This presentation will take place within the framework of a specific session that the American Heart Association (AHA) has decided to dedicate to resistant hypertension during its annual congress.
‘This specific session demonstrates once again the interest of the community for a new therapeutic class, such as that represented by firibastat, allowing the management of resistant arterial hypertension’, declares Bruno Besse, medical director of Quantum Genomics.
The results of the study, presented at the AHA congress by Professor Bakris, will constitute a first key step towards the filing of the registration dossier with the American and European authorities.
The FRESH study is the first pivotal phase III study aimed at evaluating the efficacy and safety of firibastat in the treatment of difficult resistant hypertension.